2. Search Result
Search Result
Results for "

SGLT1/2-IN-1

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10449
    Luseogliflozin

    TS 071

    		 SGLT Metabolic Disease
    Luseogliflozin (TS 071) is a potent, selective, orally active sodium-dependent glucose cotransporter (SGLT) 2 inhibitor, with an IC50 of 2.26 nM, about 1765-fold selectivity over SGLT1 (IC50, 3990 nM). Luseogliflozin has the protential for researching type 2 diabetes .
    Luseogliflozin
  • HY-I1120
    SGLT2-IN-1

    		SGLT Metabolic Disease
    SGLT2-IN-1 (Compound 5) is an inhibitor for sodium-dependent glucose cotransporter (SGLT2), with IC50 of 33 nM in CHO cells transfected with human SGLT2. SGLT2-IN-1 is selective for SGLT2 over SGLT1. SGLT2-IN-1 is an active metabolite of dapagliflozinactive metabolite of dapagliflozin .
    SGLT2-IN-1
  • HY-138944
    SGLT1/2-IN-1

    		SGLT Metabolic Disease
    SGLT1/2-IN-1 is a dual SGLT1/SGLT2 inhibitor extract from WO2015032272A1, compound 2 .
    SGLT1/2-IN-1
  • HY-150322
    SAR-7226

    		SGLT Metabolic Disease
    SAR-7226 is a SGLT1 and SGLT2 dual inhibitor. SAR-7226 can be used for research of type 2 diabetes .
    SAR-7226
  • HY-109092A
    rel-Licogliflozin

    rel-LIK066

    		 SGLT Metabolic Disease Inflammation/Immunology
    rel-Licogliflozin is a relative configuration of Licogliflozin (HY-109092). Licogliflozin is a sodium glucose cotransporter (SGLT1 and SGLT2) inhibitor .
    rel-Licogliflozin
  • HY-I1120R
    SGLT2-IN-1 (Standard)

    		Reference Standards SGLT Metabolic Disease
    SGLT2-IN-1 (standard) is the analytical standard for SGLT2-IN-1. This product is used for research and analytical applications. SGLT2-IN-1 (Compound 5) is an inhibitor for sodium-dependent glucose cotransporter (SGLT2), with IC50 of 33 nM in CHO cells transfected with human SGLT2. SGLT2-IN-1 is selective for SGLT2 over SGLT1. SGLT2-IN-1 is an active metabolite of dapagliflozinactive metabolite of dapagliflozin.
    SGLT2-IN-1 (Standard)
  • HY-186207
    Demethyl-LX2761

    		SGLT Metabolic Disease
    Demethyl-LX2761 is a selective sodium-glucose cotransporter 1 (SGLT1) inhibitor. Demethyl-LX2761 can be used for the research of type 2 diabetes .
    Demethyl-LX2761
  • HY-10449R
    Luseogliflozin (Standard)

    TS 071 (Standard)

    		 Reference Standards SGLT Metabolic Disease
    Luseogliflozin (Standard) is the analytical standard of Luseogliflozin (HY-10449). This product is intended for research and analytical applications. Luseogliflozin (TS 071) is a potent, selective, orally active sodium-dependent glucose cotransporter (SGLT) 2 inhibitor, with an IC50 of 2.26 nM, about 1765-fold selectivity over SGLT1 (IC50, 3990 nM). Luseogliflozin has the protential for researching type 2 diabetes .
    Luseogliflozin (Standard)
  • HY-180528
    SGLT2-IN-6

    		SGLT Dipeptidyl Peptidase Metabolic Disease
    SGLT2-IN-6 (Compound 101) is an orally active SGLT2 inhibitor with IC₅₀ values for SGLT2, SGLT1, and DPP4 of 0.8, 6.7, and 72 nM respectively. SGLT2-IN-6 controls blood sugar levels in diabetic rat models and increases the levels of active GLP-1. SGLT2-IN-6 can be used for the study of type 2 diabetes .
    SGLT2-IN-6
  • HY-180527
    SGLT2-IN-5

    		SGLT Dipeptidyl Peptidase Metabolic Disease
    SGLT2-IN-5 (Compound 99) is an orally active SGLT2 inhibitor with IC₅₀ values for SGLT2, SGLT1, and DPP4 of 0.8, 23, and 58 nM respectively. SGLT2-IN-5 controls blood sugar levels in diabetic rat models and increases the levels of active GLP-1. SGLT2-IN-5 can be used for the study of type 2 diabetes .
    SGLT2-IN-5
  • HY-180784
    Hypoglycemic agent 4

    		Drug Derivative Dipeptidyl Peptidase SGLT GLUT Metabolic Disease
    Hypoglycemic agent 4 (Compound 5b) is a tetrahydroacridine derivative with orally active hypoglycemic activity. Hypoglycemic agent 4 has a good binding affinity for the key diabetic targets: DPP-IV, SGLT1, and GLUT2. Hypoglycemic agent 4 can inhibit glucose diffusion. Hypoglycemic agent 4 can reduce fasting blood sugar in Streptozotocin (HY-13753)-induced diabetic rats and its effect is comparable to Gliclazide (HY-B0753). Hypoglycemic agent 4 can be used for research of type 2 diabetes .
    Hypoglycemic agent 4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: